Evaluation of commercial Guardant360 ctDNA test in metastatic prostate cancer
Circulating tumor DNA (ctDNA) sequencing provides a minimally-invasive method for tumor molecular stratification. We compared the commercial Guardant360 ctDNA test to an academic sequencing approach for profiling of metastatic prostate cancer. Plasma cell-free DNA (cfDNA) from 24 patients was sequenced with a validated, prostate cancer specific targeted research panel, and sent for simultaneous Guardant360 analysis.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
|Illumina HiSeq 2500
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.
JCO Precis Oncol 3: 2019 PO.19.00014